The $1 Trillion Cardiovascular Reset
One of my biggest obsessions right now is the pharmaceutical sector.
If you’ve been reading Macro Notes for a while, you probably followed me down the GLP-1 rabbit hole back in January.
That thesis is playing out — the oral formulations are advancing through Phase 3, and two of the three names I flagged are up significantly since the original write-up.
But today I want to talk about something else.
Something most of my readers haven’t asked about. Something that doesn’t make headlines on CNBC and isn’t trending on FinTwit.
A space where the asymmetry is, in my opinion, even more compelling than the obesity trade was eighteen months ago — precisely because nobody is paying attention yet.
I’ve spent the last six weeks building a position.
I’m now about 7% of my portfolio into this thesis.
And I want to walk you through exactly why — starting with a story that begins in a Paris hospital in 1990 and ends with Eli Lilly writing a $1.3 billion check last June.
In the early 1990s, a young French-Lebanese geneticist named Catherine Boileau was working at Hôpital Necker in Paris, studying French families cursed with strange and brutal cardiovascular profiles.
Astronomical cholesterol levels. Heart attacks at 35. Sudden deaths before 40. Statins had just hit the market — they didn’t work on these patients. The known mutations of the LDL receptor? Absent. Something else was driving it.
It took thirteen years of work. In 2003, Boileau’s team published the discovery of a previously unknown gene: PCSK9.
A “gain-of-function” mutation in this gene caused the body to overproduce the protein, which destroyed the LDL receptors in the liver, which let cholesterol accumulate in the blood, which ended up killing entire families three generations in a row.
A few months after the publication, 4,800 miles away at UT Southwestern Medical Center in Dallas, another geneticist — Helen Hobbs — read Boileau’s paper and had the inverse intuition.
If a mutation that activates PCSK9 caused catastrophic cholesterol levels, maybe a mutation that deactivates it would produce the opposite: lifelong low cholesterol, lifelong protection against heart attacks.
Hobbs had access to a rare dataset: the Dallas Heart Study, 3,500 people genetically and physiologically profiled. She went looking for the low outliers.
She found them.
One in fifty African Americans in the Dallas cohort carried a mutation that deactivated PCSK9. Their average LDL cholesterol was 40% lower than the general population.
But that wasn’t the interesting number.
The interesting number was the lifetime reduction in major cardiovascular events: 88%.
Eighty-eight percent. A random genetic mutation, inherited at birth, with no side effects, no prescription, no doctor’s appointment — produced something that no statin, no ezetimibe, no Mediterranean diet, no preventive cardiology protocol in the world has ever come close to matching.
Twenty-two years later, several biotech companies are racing to reproduce that mutation on demand, in any patient, through a single two-hour intravenous infusion.
And on June 17, 2025, Eli Lilly paid $1.3 billion in cash to acquire the one with the most convincing data.
To understand why that price tag matters, you have to understand how dominant statins remain in modern medicine.
The global market is roughly $16 billion in 2025, projected to hit $20 billion by 2032. But revenues don’t tell the real story — volumes do.
More than 120 million statin prescriptions are written annually worldwide.
In the United States alone, over 25 million adults are on long-term statin therapy. 94 million American adults have total cholesterol above 200 mg/dL, creating a massive pool of potential patients. Statins appear in over 90% of cardiovascular treatment guidelines globally.
It’s probably the most prescribed therapeutic class in the history of medicine.
But the more I dug into the research — clinical trials, meta-analyses, real-world adherence data — the more an obvious problem emerged.
Statins work. They save lives. The problem isn’t efficacy.
The problem is that patients stop taking them.
A consensus statement from the European Atherosclerosis Society lays out the discontinuation reality in numbers that should frankly embarrass the industry:
Up to 75% of patients discontinue within 2 years of initiation
10 to 25% of users report muscle symptoms (myalgia, weakness, cramping)
Among those who quit: 60% cite muscle pain as the primary reason, 16% cite cost
Cardiovascular mortality is 50% higher in elderly patients with low adherence (24% vs 16% for high-adherence patients)
Three out of four patients abandon their treatment before 24 months. Most of them don’t even realize they’ve stopped protecting themselves — they miss doses, leave on vacation without renewing, eventually decide it’s “not doing anything” because they don’t feel anything.
This isn’t a product problem. It’s a model problem: prescribing a daily pill, for life, to asymptomatic people, to prevent an abstract event 15 years in the future — that’s asking human nature to do exactly what it does worst.
So you end up in this strange situation: a $16 billion market where the delivery mechanism is fundamentally broken for 75% of users.
Pharma companies aren’t worried about it because they sell pills regardless. But for anyone who can solve the adherence problem, the prize is enormous.
And here’s where it gets really interesting — because there’s a second problem, much bigger, that almost nobody talks about.
It’s called Lp(a). Lipoprotein “little a.” Pronounced “L-P-little-a” in cardiology hallways.
Imagine a regular LDL cholesterol particle, but with an extra protein — apolipoprotein(a) — covalently attached to it. That extra protein gives the particle unique properties: it’s pro-thrombotic, pro-inflammatory, and particularly effective at calcifying aortic valves and clogging coronary arteries.
Here are the numbers that genuinely surprised me when I first ran them:
One in five people worldwide has elevated Lp(a). That’s roughly 1.4 billion people.
Lp(a) levels are entirely determined by genetics. Not by diet. Not by exercise. Not by weight. You’re born with your level and you die with it — unless someone intervenes pharmacologically.
But here’s the kicker, the one that changes everything: statins have no effect on Lp(a). They might even raise it slightly in certain populations. Every cardiovascular drug currently approved — statins, ezetimibe, PCSK9 antibodies, fibrates — leaves Lp(a) untouched.
As of today, in 2026, there is zero FDA-approved therapy specifically targeting Lp(a) reduction.
Not one.
And yet Lp(a) is causally linked to coronary artery disease, ischemic stroke, calcific aortic valve stenosis, and likely atrial fibrillation — according to joint statements from the American Heart Association and the European Atherosclerosis Society.
This isn’t a growth market. This is a market that doesn’t exist yet.
Phase 2 trials on Lp(a)-targeting molecules have shown numbers that are, by biotech standards, almost embarrassing in their consistency:
Olpasiran (Amgen): 94% Lp(a) reduction at 36 weeks, dosed every 3 months
Pelacarsen (Novartis/Ionis): ~80% reduction, monthly injection
Lepodisiran (Eli Lilly): >90% reduction with a single dose lasting 180 days
CTX320 (CRISPR Therapeutics): up to 73% reduction via one-shot gene editing
Four different drugs, four different mechanisms, all wiping out a causal cardiovascular risk factor that affects 1.4 billion people and has zero approved competitor. That’s the kind of setup that comes along once a decade.
Which brings me back to the Lilly-Verve transaction. Let’s walk through the timeline carefully, because the price tag only makes sense in context:
2023: Lilly pays $60 million upfront to Verve Therapeutics for a preclinical cardiovascular partnership
Later in 2023: Lilly pays an additional $250 million to Beam Therapeutics for opt-in rights to Verve’s PCSK9, ANGPTL3 and one undisclosed program
April 2025: Verve publishes its Heart-2 Phase 1b data for VERVE-102, a gene editing therapy that switches off PCSK9 in the liver. Across 14 patients, after a single infusion: mean LDL-C reduction of 53%, maximum 69%. No serious adverse events. No clinically significant hepatic abnormalities.
April 2025: FDA grants Fast Track designation to VERVE-102
June 17, 2025: Eli Lilly announces full acquisition of Verve for up to $1.3 billion in cash — a 67.5% premium over the prior closing price
Eugene Braunwald — the global dean of cardiology, founder of the TIMI Study Group at Harvard, the man behind half the pivotal cardiovascular trials of the past 40 years — publicly stated that these data suggest the dawn of a new era in cardiovascular treatment, where a single dose might deliver lifelong control of LDL-C.
When Braunwald says that, the industry listens.
And Lilly just paid $1.3 billion for Phase 1b data on fourteen patients. Not Phase 2. Not Phase 3. Fourteen patients.
Why?
Because if VERVE-102 works in Phase 2 and 3, the target market isn’t the $16 billion statin market. It’s the global cardiovascular prevention spend — which exceeds $1 trillion in cumulative annual expenditure worldwide, between prescriptions, interventional cardiology, and hospitalization costs from cardiac events.
Lilly isn’t buying a therapy. Lilly is buying a long-dated option on the total transformation of a daily-prescription business model into a single-intervention model. At $1.3 billion, that option looks expensive on a fourteen-patient trial. On a $1 trillion target market, it looks like a steal.
After several weeks pulling this apart, I came to see three structural constraints holding back the cardiovascular market today — and that one-shot therapies dissolve simultaneously.
1. The adherence wall
75% discontinuation in 2 years. With a one-shot therapy, compliance is no longer a variable. This isn’t a 10% or 30% improvement — it’s the complete elimination of a structural problem that degrades the entire clinical ROI of current treatment.
2. The non-existent Lp(a) market
1.4 billion people at genetic risk. Zero approved therapy today. This is a market that will be created from scratch the moment the first FDA approval lands — likely 2027-2028 for pelacarsen, followed by olpasiran and the gene editing therapies.
3. The “lifelong premium”
Payers (Medicare, private insurers) increasingly calculate value on 30+ year NPV. A one-shot therapy priced at $250-500K becomes cost-effective against $50K cumulative PCSK9 antibody spend + monitoring + averted event costs over a patient’s lifetime. Autoimmune CAR-T therapies have already validated this pricing model at $500-750K per dose.
The market expansion math is, to be honest, almost uncomfortable to write down — but here it is, at conservative assumptions:
Eligible US population: 25M on statins + 60M with elevated Lp(a) = >80M potential candidates
5% penetration over 10 years = 4M treated patients
Average pricing: $350K (between PCSK9 antibody and CAR-T benchmarks)
Cumulative US market potential: ~$1.4 trillion over 10 years
I know how that number reads. But it’s exactly the kind of expansion we saw in oncology when CAR-T therapies arrived, and what we’re watching unfold right now in obesity with GLP-1s. Every time a one-shot or transformative therapy replaces a chronic prescription model, the addressable market doesn’t grow linearly — it gets redrawn.
The market isn’t pricing this possibility in. Not yet.
And this is where timing becomes critical.
2026 is the year multiple major catalysts converge:
H1 2026 — Phase 3 readout for pelacarsen (Novartis/Ionis), the Lp(a) HORIZON trial, 8,323 patients. This is the first cardiovascular outcomes trial ever conducted on an Lp(a)-targeting therapy. If MACE (major adverse cardiovascular events) drops significantly, that’s the validation the cardiology community has been waiting on for 20 years. Regulatory submissions expected H2 2026.
Throughout 2026 — CRISPR Therapeutics update on the CTX320 program (Lp(a)), with potential transition to CTX321 (second generation, 2x more potent in preclinical).
Mid-2026 to late 2026 — Final Heart-2 dose escalation data (VERVE-102) and Phase 2 launch under Lilly’s umbrella.
2026-2027 — First interventional results from olpasiran (Amgen) on coronary plaque progression (OCEAN(a)-CCTA trial, starting March 2026).
If even one of these readouts succeeds, the valuation of the companies running them re-rates overnight. Institutional money — which today largely ignores these tickers because they’re “early stage biotech” — piles in once pivotal data prints. By the time that happens, the easy money is gone.
The PCSK9 antibody story makes this clear. Gene discovery: 2003. First FDA approval: 2015. Twelve years, considered “exceptionally fast” at the time. Today, we’re talking about one-shot therapies through gene editing on the same target — twenty-two years after Boileau’s original discovery, but with an innovation compression curve that keeps accelerating.
When a technological domain goes from “academic discovery” to “$1.3 billion acquisition on Phase 1b data” in two decades, you’re rarely too early.
You’re usually right on time.
Over the past six weeks, I’ve built positions in three companies that I believe are best positioned to capture this transformation. Combined, they represent about 7% of my total portfolio — my second-largest thematic allocation, right after AI infrastructure.
These aren’t speculative lottery tickets. These are late-stage clinical programs with published Phase 1b or Phase 2 data, technology platforms validated by Big Pharma partnerships, experienced management teams, and concrete catalysts arriving in the next 12-18 months.
One of the companies already has a commercialized product funding its pipeline — drastically reducing dilution risk. Another has a structural partnership with a top-tier pharmaceutical company that absorbs Phase 3 development costs. The third has the most compelling efficacy data, but carries the highest execution risk — and arguably the highest upside if it works.
In the rest of this analysis, I’m going to reveal:
The three exact tickers I’m positioned in — current market cap, portfolio allocation, and why each plays a different role in the thesis
Detailed Phase 1b/2 breakdown — VERVE-102 vs CTX320 vs olpasiran/pelacarsen, head-to-head comparison on efficacy, durability, and safety profile
Catalyst calendar month by month through 2026-2027 — when to buy, when to take profits, when to cut
Valuation analysis — what these companies are worth today vs Phase 3 success scenarios (the multiples are compelling)
Risk factors I’m tracking — off-target effects, gene editing durability, LNP immunogenicity, and why I’m comfortable with 7% portfolio exposure
Why the next 12-18 months is the critical window — before Phase 3 data fully de-risks the thesis and institutional money arrives
This is the most compelling risk-reward I’ve found in biotech since the oral GLP-1 opportunity I wrote about in January. The market is massive and structurally jammed by an obsolete delivery model.
The incumbents can’t easily defend against a one-shot therapy — they’re structurally trapped by their own chronic-prescription molecules. And the companies building the solution are trading like nobody’s reading the same papers I am.
Let me show you exactly what I’ve found, and why I’m betting 7% of my portfolio on this thesis playing out.